Published in PLoS One on March 28, 2014
In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2. Retrovirology (2015) 0.82
The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1. Antimicrob Agents Chemother (2015) 0.75
Assessment of the Cavidi ExaVir™ Load assay for monitoring plasma viral load in HIV-2 infected patients. J Clin Microbiol (2017) 0.75
MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res (2004) 168.89
Jalview Version 2--a multiple sequence alignment editor and analysis workbench. Bioinformatics (2009) 31.84
Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases. Mol Cell Biol (1992) 6.77
Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro. J Virol (1992) 6.07
Domains of the integrase protein of human immunodeficiency virus type 1 responsible for polynucleotidyl transfer and zinc binding. Proc Natl Acad Sci U S A (1993) 3.99
Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med (2013) 3.58
Mutational analysis of the integrase protein of human immunodeficiency virus type 2. Proc Natl Acad Sci U S A (1992) 3.55
Identification of amino acid residues critical for endonuclease and integration activities of HIV-1 IN protein in vitro. Virology (1992) 3.43
Identification of the catalytic and DNA-binding region of the human immunodeficiency virus type I integrase protein. Nucleic Acids Res (1993) 3.42
In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother (2010) 2.89
Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction. EMBO J (1998) 2.84
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother (2008) 2.61
A soluble active mutant of HIV-1 integrase: involvement of both the core and carboxyl-terminal domains in multimerization. J Biol Chem (1996) 2.58
The core and carboxyl-terminal domains of the integrase protein of human immunodeficiency virus type 1 each contribute to nonspecific DNA binding. J Virol (1994) 2.56
Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization, and enhances catalytic activity. Proc Natl Acad Sci U S A (1996) 2.46
Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther (2004) 2.45
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis (2012) 2.43
Critical contacts between HIV-1 integrase and viral DNA identified by structure-based analysis and photo-crosslinking. EMBO J (1997) 2.42
HIV integrase structure and function. Adv Virus Res (1999) 2.08
Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol (2011) 1.95
Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther (2007) 1.93
Characterization of a DNA binding domain in the C-terminus of HIV-1 integrase by deletion mutagenesis. Nucleic Acids Res (1993) 1.79
Human immunodeficiency virus type 1 integrase: arrangement of protein domains in active cDNA complexes. EMBO J (2001) 1.77
Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev (2009) 1.76
Zn2+ promotes the self-association of human immunodeficiency virus type-1 integrase in vitro. Biochemistry (1997) 1.69
HIV-2: the forgotten AIDS virus. Trends Microbiol (2008) 1.66
Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology (2013) 1.66
Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J Antimicrob Chemother (2009) 1.59
Baseline susceptibility of primary HIV-2 to entry inhibitors. Antivir Ther (2012) 1.56
HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother (2008) 1.47
Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J Antimicrob Chemother (2006) 1.33
Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness. J Acquir Immune Defic Syndr (2010) 1.30
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother (2008) 1.30
Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother (2009) 1.27
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob Agents Chemother (2006) 1.25
Biophysical and enzymatic properties of the catalytic domain of HIV-1 integrase. J Biol Chem (1994) 1.22
CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort. AIDS (2006) 1.19
Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrob Agents Chemother (2013) 1.17
Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure. Antimicrob Agents Chemother (2009) 1.16
Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France. J Clin Microbiol (2004) 1.15
Use of patient-derived human immunodeficiency virus type 1 integrases to identify a protein residue that affects target site selection. J Virol (2001) 1.12
Role of the nonspecific DNA-binding region and alpha helices within the core domain of retroviral integrase in selecting target DNA sites for integration. J Biol Chem (2001) 1.12
Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen. AIDS (2008) 1.08
Baseline plasma viral load and CD4 cell percentage predict survival in HIV-1- and HIV-2-infected women in a community-based cohort in The Gambia. J Acquir Immune Defic Syndr (2005) 1.07
Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance. J Infect Dis (2009) 1.06
The core domain of HIV-1 integrase recognizes key features of its DNA substrates. J Biol Chem (1997) 1.05
Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. J Antimicrob Chemother (2010) 1.04
The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates. AIDS (2010) 1.04
Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups. J Acquir Immune Defic Syndr (2004) 1.03
G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not. Retrovirology (2011) 1.03
Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc. Antiviral Res (2010) 1.02
Raltegravir treatment response in an HIV-2 infected patient: a case report. AIDS (2008) 1.01
Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity. J Clin Virol (2009) 1.00
Biochemical and virological analysis of the 18-residue C-terminal tail of HIV-1 integrase. Retrovirology (2009) 0.99
Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients. AIDS (2008) 0.96
In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572. AIDS (2010) 0.93
Dynamics of raltegravir resistance profile in an HIV type 2-infected patient. AIDS Res Hum Retroviruses (2009) 0.92
Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy. Antivir Ther (2008) 0.92
Are fusion inhibitors active against all HIV variants? AIDS Res Hum Retroviruses (2004) 0.91
HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa. PLoS One (2011) 0.91
High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART. AIDS (2006) 0.91
Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir. Retrovirology (2010) 0.90
Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics. PLoS One (2013) 0.89
Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir. Antimicrob Agents Chemother (2010) 0.89
Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance. AIDS (2011) 0.86
Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatment-experienced HIV type 2 patients. AIDS Res Hum Retroviruses (2008) 0.86
Drug resistance mutations in patients infected with HIV-2 living in Spain. J Antimicrob Chemother (2011) 0.86
Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens. PLoS One (2012) 0.81
Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal. Antivir Ther (2011) 0.78
Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient. AIDS (2011) 0.77
Mutations selected in HIV-2-infected patients failing a regimen including atazanavir. J Antimicrob Chemother (2012) 0.81